

# Moritz FÃ¼rstenau

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5550745/publications.pdf>

Version: 2024-02-01

22  
papers

399  
citations

840776

11  
h-index

794594

19  
g-index

22  
all docs

22  
docs citations

22  
times ranked

613  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2022, 139, 177-187.   | 1.4 | 40        |
| 2  | Obinutuzumab (GA-101), ibrutinib, and venetoclax (G1V) frontline treatment for high-risk chronic lymphocytic leukemia. <i>Blood</i> , 2022, 139, 1318-1329.  | 1.4 | 30        |
| 3  | Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax. <i>Clinical Cancer Research</i> , 2022, 28, 4203-4211.   | 7.0 | 9         |
| 4  | Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. <i>Leukemia</i> , 2022, 36, 2125-2128.  | 7.2 | 4         |
| 5  | Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial. <i>Haematologica</i> , 2021, 106, 543-554.                           | 3.5 | 12        |
| 6  | Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance. <i>Cancers</i> , 2021, 13, 1336.  | 3.7 | 20        |
| 7  | B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2021, 137, 2267-2271.  | 1.4 | 10        |
| 8  | Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations. <i>Blood</i> , 2021, 138, 1805-1816.  | 1.4 | 7         |
| 9  | Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E457-E460.  | 4.1 | 3         |
| 10 | COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.   | 7.2 | 57        |
| 11 | Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 924-928. | 7.2 | 4         |
| 12 | Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. <i>Leukemia</i> , 2020, 34, 1177-1181.  | 7.2 | 6         |
| 13 | COVID-19 among fit patients with CLL treated with venetoclax-based combinations. <i>Leukemia</i> , 2020, 34, 2225-2229.  | 7.2 | 39        |
| 14 | COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2020, 105, 508-511.  | 2.2 | 10        |
| 15 | Invasive Aspergillosis in Patients Treated With Ibrutinib. <i>HemaSphere</i> , 2020, 4, e309.  | 2.7 | 9         |
| 16 | How to approach CLL in clinical practice. <i>Hematological Oncology</i> , 2019, 37, 38-42.   | 1.7 | 15        |
| 17 | Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 2144-2154.  | 3.5 | 20        |
| 18 | Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?. <i>HemaSphere</i> , 2019, 3, e287.   | 2.7 | 33        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Relapsed disease and aspects of undetectable MRD and treatment discontinuation. Hematology American Society of Hematology Education Program, 2019, 2019, 482-489.  | 2.5 | 2         |
| 20 | Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harboring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation). Blood, 2018, 132, 694-694.                      | 1.4 | 16        |
| 21 | Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 4430-4430.                  | 1.4 | 1         |
| 22 | Efficacy of Mefloquine Intermittent Preventive Treatment in Pregnancy Against Schistosoma haematobium Infection in Gabon: A Nested Randomized Controlled Assessor-Blinded Clinical Trial. Clinical Infectious Diseases, 2013, 56, e68-e75. | 5.8 | 52        |